These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38262300)

  • 1. The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.
    Cavalcante FP; Zerwes FP; Souza ABA; Ziegelmann PK; Alcantara R; Cardoso A; Mattar A; Millen EC; Frasson AL
    Eur J Surg Oncol; 2024 Mar; 50(3):107967. PubMed ID: 38262300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Chen M; Li S; Huang M; Guo J; Huang X; Guo W; Chen L; Lin Y; Jacobs L; Wang C; Fu F
    Breast Cancer Res Treat; 2022 Nov; 196(2):267-277. PubMed ID: 36100784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
    Cabıoğlu N; Karanlık H; Kangal D; Özkurt E; Öner G; Sezen F; Yılmaz R; Tükenmez M; Önder S; İğci A; Özmen V; Dinççağ A; Engin G; Müslümanoğlu M
    Ann Surg Oncol; 2018 Oct; 25(10):3030-3036. PubMed ID: 29978371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.
    Chavda J; Mishra A; Silodia A; Yadav SK; Sharma DB; Sharma D; Khandare M
    Breast Cancer Res Treat; 2022 May; 193(1):105-110. PubMed ID: 35246773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.
    DeSnyder SM; Mittendorf EA; Le-Petross C; Krishnamurthy S; Whitman GJ; Ueno NT; Woodward WA; Kuerer HM; Akay CL; Babiera GV; Yang W; Lucci A
    Clin Breast Cancer; 2018 Feb; 18(1):e73-e77. PubMed ID: 28755879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node.
    Fuertes Manuel J; Kohan S; Jordà Solé M; Mateu Hidalgo I; Miralles Curto M; Aguiló Sagristà O; Aguilar Alomá E; Peña González K; Lafuerza Torres A; Melé Olivé M; Repkova J; Montero Jaime MJ; Gumà Padró J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):284-291. PubMed ID: 35597764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy.
    Sparger CC; Hernandez AE; Rojas KE; Khan K; Halfteck GG; Möller M; Avisar E; Goel N; Crystal JS; Kesmodel SB
    World J Surg Oncol; 2024 Jul; 22(1):199. PubMed ID: 39075403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
    Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
    JAMA Oncol; 2024 Jun; 10(6):793-798. PubMed ID: 38662396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
    Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
    Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in patients with node-positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta-analysis.
    Keelan S; Boland MR; Ryan ÉJ; Moran LR; Davey MG; Lloyd AJ; Elwahab S; Hill ADK
    Br J Surg; 2023 Feb; 110(3):324-332. PubMed ID: 36512473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
    Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
    Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
    Chintamani ; Tandon M; Mishra A; Agarwal U; Saxena S
    World J Surg Oncol; 2011 Feb; 9():19. PubMed ID: 21396137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
    Fernandez-Gonzalez S; Falo C; Pla MJ; Campos M; Ortega-Exposito C; Ortega R; Vicente M; Petit A; Bosch-Schips J; Bajen MT; Reyes G; Martínez E; González-Viguera J; Peñafiel J; Stradella A; Pernas S; Ponce J; Garcia-Tejedor A
    Breast Cancer Res Treat; 2024 Jul; 206(1):131-141. PubMed ID: 38635082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy.
    Tasdoven I; Balbaloglu H; Erdemir RU; Bahadir B; Guldeniz Karadeniz C
    Medicine (Baltimore); 2022 Dec; 101(52):e32545. PubMed ID: 36596061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.